TherapeuticsMD Profit Margin

The latest profit margin for TXMD is -8.73% as of June 2026. That compares with -28.35% in the prior-year period — up 69.2% year over year. That is below the Healthcare sector average of 14.41%. Investors often review this figure alongside TherapeuticsMD's historical trend and sector peers before judging valuation or financial health.

Over the past year, TXMD's profit margin moved from -28.35% to -8.73% — a 69.2% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in TherapeuticsMD's valuation or profitability profile.

Against Healthcare companies, TXMD currently prints -8.73% for profit margin, while the sector average sits near 14.41%. That is roughly 160.6% below the sector mean. Large gaps often invite a closer look at TherapeuticsMD's growth, margins, and balance sheet.

Profit Margin shows how effectively TherapeuticsMD converts resources into returns. At -8.73%, TXMD may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -28.35% in the prior-year period — up 69.2% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting TXMD's profit margin (-8.73%), review year-over-year change from -28.35%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.